Article Details

ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy

Retrieved on: 2024-09-01 23:46:35

Tags for this article:

Click the tags to see associated articles and topics

ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy. View article details on hiswai:

Excerpt

A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo